dibenzothiazyl disulfide has been researched along with Diabetes Mellitus, Type 2 in 1 studies
*Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Huang, YY; Li, J; Li, XK; Mao, F; Ni, SS; Ren, YL; Song, RR; Wan, J; Xu, YX; Zhang, C; Zhu, J | 1 |
1 other study(ies) available for dibenzothiazyl disulfide and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Development of disulfide-derived fructose-1,6-bisphosphatase (FBPase) covalent inhibitors for the treatment of type 2 diabetes.
Topics: Animals; Blood Glucose; Cysteine; Diabetes Mellitus, Type 2; Disulfides; Enzyme Inhibitors; Fructose-Bisphosphatase; Male; Mice; Structure-Activity Relationship | 2020 |